Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04523142 · ClinicalTrials.gov registry record · Phase 3
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004
A Phase 3 study, sponsored by Novaliq.
- Completed
- Registry status
- Phase 3
- Development phase
- 202
- Enrollment target
NCT04523142 is a Phase 3 study that has completed, run by Novaliq. The registered enrollment target is 202 participants.
The verdict
NCT04523142, a Phase 3 study, has completed, sponsored by Novaliq.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 202 participants
- Enrollment target
Study Summary
The objective of this trial is to evaluate safety and tolerability of CyclASol during long-term use in subjects with Dry Eye Disease.
Interventions
- DRUG CyclASol Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2021-01-04 |
| Est. Completion | 2022-05-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04523142
The ClinicalTrials.gov registry entry for NCT04523142 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novaliq, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CyclASol Ophthalmic Solution is the first listed.
NCT04523142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04523142 about?
NCT04523142 is a clinical study titled "CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004". The objective of this trial is to evaluate safety and tolerability of CyclASol during long-term use in subjects with Dry Eye Disease.
What is the current status of trial NCT04523142?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 202 participants. The study started on 2021-01-04. Estimated completion is 2022-05-23.
What interventions are being tested in trial NCT04523142?
The interventions under investigation include: CyclASol Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT04523142?
This trial is sponsored by Novaliq, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.